-
1
-
-
0026098581
-
Gonadotrophin-releasing hormone and its analogues
-
Conn PM, Crowley WF Jr,. Gonadotrophin-releasing hormone and its analogues. N Engl J Med 1991; 324: 93-103.
-
(1991)
N Engl J Med
, vol.324
, pp. 93-103
-
-
Conn, P.M.1
Crowley, Jr.W.F.2
-
2
-
-
33645915874
-
Comparison of single-agent androgen suppression for advanced prostate cancer
-
Lepor H,. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005; 7 (Suppl. 5): S3-12.
-
(2005)
Rev Urol
, vol.7
, Issue.SUPPL. 5
-
-
Lepor, H.1
-
3
-
-
0022367715
-
Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer
-
Waxman J, Man A, Hendry WF, et al., Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J 1985; 291: 1387-8. (Pubitemid 16212355)
-
(1985)
British Medical Journal
, vol.291
, Issue.6506
, pp. 1387-1388
-
-
Waxman, J.1
Man, A.2
Hendry, W.F.3
-
4
-
-
0025688334
-
Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
-
Thompson IM, Zeidman EJ, Rodriguez FR,. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144: 1479-80.
-
(1990)
J Urol
, vol.144
, pp. 1479-1480
-
-
Thompson, I.M.1
Zeidman, E.J.2
Rodriguez, F.R.3
-
5
-
-
0022973082
-
Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate
-
Boccon-Gibod L, Laudat MH, Dugue MA, et al., Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by LHRH analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 1986; 12: 400-2. (Pubitemid 17212964)
-
(1986)
European Urology
, vol.12
, Issue.6
, pp. 400-402
-
-
Boccon-Gibod, L.1
Laudat, M.H.2
Dugue, M.A.3
Steg, A.4
-
6
-
-
50849110501
-
Degarelix: A novel gonadotrophin-releasing hormone (GnRH) blocker - Results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer
-
Van Poppel H, Tombal B, de la Rosette JM, et al., Degarelix: a novel gonadotrophin-releasing hormone (GnRH) blocker-results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805-13.
-
(2008)
Eur Urol
, vol.54
, pp. 805-813
-
-
Van Poppel, H.1
Tombal, B.2
De La Rosette, J.M.3
-
7
-
-
56649116179
-
The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
-
Klotz L, Boccon-Gibod L, Shore ND, et al., The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8.
-
(2008)
BJU Int
, vol.102
, pp. 1531-1538
-
-
Klotz, L.1
Boccon-Gibod, L.2
Shore, N.D.3
-
8
-
-
53249121469
-
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
-
Gittelman M, Pommerville PJ, Persson B-E, et al., A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986-92.
-
(2008)
J Urol
, vol.180
, pp. 1986-1992
-
-
Gittelman, M.1
Pommerville, P.J.2
Persson, B.-E.3
-
9
-
-
79955044776
-
-
LUPRON DEPOT 7.5 mg Package Insert, 03-A067-R19; Revised: December, 2007
-
LUPRON DEPOT 7.5 mg Package Insert, 03-A067-R19; Revised: December, 2007.
-
-
-
-
10
-
-
0032955357
-
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer
-
DOI 10.1046/j.1464-410x.1999.00028.x
-
Sarsody MF, Schelhammer PF, Soloway MS, et al., Endocrine effects, efficacy and tolerability of 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999; 83: 801-6. (Pubitemid 29224400)
-
(1999)
BJU International
, vol.83
, Issue.7
, pp. 801-806
-
-
Sarosdy, M.F.1
Schellhammer, P.F.2
Soloway, M.S.3
Vogelzang, N.J.4
Crawford, E.D.5
Presti, J.6
Chodak, G.W.7
Mitchell, P.8
Porter, L.9
-
11
-
-
0033900377
-
Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm
-
Oefelein MG, Cornum R,. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-9. (Pubitemid 30637611)
-
(2000)
Journal of Urology
, vol.164
, Issue.3
, pp. 726-729
-
-
Oefelein, M.G.1
Cornum, R.2
-
12
-
-
33746901635
-
Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer
-
DOI 10.1159/000093907
-
Morote J, Esquena S, Abascal JM, et al., Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006; 77: 135-8. (Pubitemid 44195773)
-
(2006)
Urologia Internationalis
, vol.77
, Issue.2
, pp. 135-138
-
-
Morote, J.1
Esquena, S.2
Abascal, J.M.3
Trilla, E.4
Cecchini, L.5
Raventos, C.X.6
Catalan, R.7
Reventos, J.8
-
13
-
-
29044442028
-
Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer
-
DOI 10.1016/j.eururo.2005.09.009, PII S0302283805005816
-
Yri OE, Bjoro T, Fossa SD,. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-8. (Pubitemid 41789955)
-
(2006)
European Urology
, vol.49
, Issue.1
, pp. 54-58
-
-
Yri, O.E.1
Bjoro, T.2
Fossa, S.D.3
-
14
-
-
77149159440
-
Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance?
-
Perachino M, Cavalli V, Bravi F,. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105: 648-51.
-
(2010)
BJU Int
, vol.105
, pp. 648-651
-
-
Perachino, M.1
Cavalli, V.2
Bravi, F.3
-
16
-
-
77956640362
-
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke
-
Hayes JH, Chen M-H, Moran BJ,. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010; 106: 979-85.
-
(2010)
BJU Int
, vol.106
, pp. 979-985
-
-
Hayes, J.H.1
Chen, M.-H.2
Moran, B.J.3
-
17
-
-
34250345421
-
Determining the optimal initiation and maintenance doses of degarelix for hormone therapy of prostate cancer patients
-
Iversen P, Van Poppel H, Tammela T, et al., Determining the optimal initiation and maintenance doses of degarelix for hormone therapy of prostate cancer patients. Urology 2006; 68 (Suppl. 5A): 102.
-
(2006)
Urology
, vol.68
, Issue.SUPPL. 5A
, pp. 102
-
-
Iversen, P.1
Van Poppel, H.2
Tammela, T.3
-
18
-
-
0030906899
-
High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle- stimulating hormone, and testosterone in normal men
-
Behre HM, Kleisch S, Pühse G, et al., High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress luteinizing hormone, follicle-stimulating hormone and testosterone in normal men. J Clin Endocrinol Metab 1997; 82: 1403-8. (Pubitemid 27200409)
-
(1997)
Journal of Clinical Endocrinology and Metabolism
, vol.82
, Issue.5
, pp. 1403-1408
-
-
Behre, H.M.1
Kliesch, S.2
Puhse, G.3
Reissmann, T.4
Nieschlag, E.5
-
19
-
-
0035516095
-
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
-
McLeod D, Zinner N, Tomera K, et al., A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 756-61.
-
(2001)
Urology
, vol.58
, pp. 756-761
-
-
McLeod, D.1
Zinner, N.2
Tomera, K.3
-
20
-
-
0036128522
-
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer
-
Trachtenberg J, Gittleman M, Steidle C, et al., A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 1670-4. (Pubitemid 34240698)
-
(2002)
Journal of Urology
, vol.167
, Issue.4
, pp. 1670-1674
-
-
Trachtenberg, J.1
Gittleman, M.2
Steidle, C.3
Barzell, W.4
Friedel, W.5
Pessis, D.6
Fotheringham, N.7
Campion, M.8
Garnick, M.B.9
-
22
-
-
33646036678
-
FSH directly regulates bone mass
-
Sun L, Peng Y, Sharrow AC, et al., FSH directly regulates bone mass. Cell 2006; 125: 247-60.
-
(2006)
Cell
, vol.125
, pp. 247-260
-
-
Sun, L.1
Peng, Y.2
Sharrow, A.C.3
-
23
-
-
77954125660
-
FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women
-
Rendina D, Gianfrancesco F, De Filipo G, et al., FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol 2010; 163: 165-72.
-
(2010)
Eur J Endocrinol
, vol.163
, pp. 165-172
-
-
Rendina, D.1
Gianfrancesco, F.2
De Filipo, G.3
-
24
-
-
84855309320
-
Open label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27)
-
Miller K, Rüssel C, Goble S, et al., Open label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). Eur Urol Suppl 2010; 9: 76.
-
(2010)
Eur Urol Suppl
, vol.9
, pp. 76
-
-
Miller, K.1
Rüssel, C.2
Goble, S.3
|